Linical Co., Ltd.
2183・Standard Market・Services
Governance
The company operates as a company with an audit and supervisory committee, comprising 6 directors (of which 5 are outside directors, an outside ratio of 83.3%), with outside directors holding a majority. It has established voluntary nomination and compensation committees, in both of which independent outside directors hold a majority and serve as chairperson.
Risk Management
The company has established a Risk Management Committee, under which executive officer CXOs conduct risk identification, assessment, and monitoring across overseas group companies for their respective areas of responsibility, and report to the Board of Directors. A system has been put in place to establish a Crisis Management Team to minimize damage in the event a significant risk materializes.
Shareholder Returns
Basic policy is a year-end dividend paid once per year, with efforts toward stable profit distribution taking business performance into account. For FY2026 (ending March 2026), a dividend of ¥8 per share was implemented (a decrease from ¥16 in the previous period). The same amount of ¥8 is planned for FY2027 (ending March 2027) as well. No numerical target for the dividend payout ratio has been disclosed.
Dividend Policy
The company positions optimizing the balance between enhancing corporate value through medium- to long-term growth and profit distribution as an important policy measure, conducting a dividend policy that takes business performance into account and striving for stable profit distribution. The basic policy is to pay a dividend from surplus once per year at the fiscal year-end, and the articles of incorporation stipulate that dividends of surplus, etc. may be determined by resolution of the Board of Directors. For FY2026 (ending March 2026), a dividend of ¥8 per share (total dividend amount of ¥180 million) was implemented. This represents a decrease from ¥16 in the previous period (FY2025, ended March 2025). The dividend for FY2027 (ending March 2027) is also planned to be ¥8 per share (dividend payout ratio of 100.4%).
ESG
The company has identified three materialities (innovative drug development, ethics and compliance, and responsibility to future generations) and set SBTi-certified GHG reduction targets (58.8% reduction in Scope 2 emissions by FY2034 (ending March 2034)). On the human capital front, the consolidated turnover rate reached 13.4% (target: 15% or below), and the company is working on talent development and improving engagement.
Last updated: June 22, 2026